Scan to Download Gate App
qrCode
More Download Options
Don't remind me again today

Citi: Initiate coverage on Shindah Biotech with a 'Buy' rating and a target price of HKD 55

Jinshi Data, November 5th, Citigroup released a research report stating that Sino Biopharmaceutical (01801.HK) announced the termination of the Fortvita subscription transaction. The company’s management stated at an investor conference on November 4th that the original intention of the transaction was to accelerate the development of the company’s overseas business, Fortvita. After the transaction was terminated, there is currently no further financing plan for Fortvita. Since the announcement of the transaction, the group’s stock price has fallen by more than 20%. Looking ahead, the bank believes that the group’s strong sales performance and overseas bed progress will sustainably restore investor confidence. Rating ‘buy’, target price of 55 Hong Kong dollars.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • 1
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)